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Summary IntroductionAldoxorubicin, a prodrug of doxoru-
bicin, binds covalently to serum albumin in the bloodstream
and accumulates in tumors. Aldoxorubicin can be adminis-
tered at doses several-fold higher than doxorubicin can, with-
out associated acute cardiotoxicity. Purpose This study fully
evaluated the pharmacokinetic profile of aldoxorubicin (se-
rum and urine). Methods Eighteen patients with advanced
solid tumors received aldoxorubicin 230 or 350 mg/m2
(equivalent in drug load to doxorubicin at doses of 170 or
260 mg/m2, respectively) once every 21 days. Blood samples
were taken in cycle 1 before aldoxorubicin infusion, and at 5,
15, 30, and 60min, and at 2, 4, 8, 12, 16, 24, 48, and 72 h after
infusion. Urine samples were taken in cycle 1 at 24, 48, and
72 h after infusion. Limited blood sampling was done in cycle
3, before aldoxorubicin infusion, and at 60min and at 2, 4, and
8 h after infusion. Results The long mean half-life (20.1–
21.1 h), narrow mean volume of distribution (3.96–4.08 L/
m2), and slow mean clearance rate (0.136–0.152 L/h/m2)
suggest that aldoxorubicin is stable in circulation and does
not accumulate readily in body compartments outside of the
bloodstream. Very little doxorubicin and its major metabolite
doxorubicinol, which has been implicated in doxorubicin-
associated cardiotoxicity, are excreted in urine. This might
explain the lack of cardiotoxicity observed thus far with
aldoxorubicin. Conclusions Our findings support dosing and
administration schemas used in an ongoing phase 3 clinical
study of aldoxorubicin in soft tissue sarcoma, and phase 2
clinical studies in small cell lung cancer, glioblastoma, and
Kaposi’s sarcoma.
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Introduction
Doxorubicin is approved, either alone or in combination with
other drugs, for treatment of numerous cancers [1,2]. Unfor-
tunately, the benefits of doxorubicin-based regimens are di-
minished by dose-dependent, drug-related toxicities, particu-
larly cardiotoxicity [3,4]. Early research suggested that the
cardiotoxicity of doxorubicin could be attributable to metab-
olism of doxorubicin to doxorubicinol and the subsequent
action of doxorubicinol on cardiac tissue [5,6]. As a result,
dose-intensive or long-term treatment with doxorubicin ex-
ceeding a cumulative dose of 550 mg/m2 is not recommended.
Aldoxorubicin is a prodrug of doxorubicin that is
derivatized at its C-13-keto position and is conjugated to a
linker consisting of an acid-sensitive hydrazine moiety, a 6-
carbon spacer, and a thiol-binding maleimide (6-
maleimidocaproic acid hydrazide) [7]. When aldoxorubicin
enters the bloodstream, this linker molecule binds rapidly
(within 5 min) and covalently to the cysteine-34 amino acid
of endogenous albumin [7]. Due to the enhanced vascular
permeability and poor lymphatic drainage that are character-
istic of tumors (enhanced permeability and retention) [8],
albumin-bound doxorubicin accumulates in the tumor and is
then released in the acidic environment of the tumor or inside
tumor cells via cleavage of the acid-sensitive hydrazine bond
between the drug and the linker [7].
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In a preliminary phase 1 study of aldoxorubicin in patients
with advanced solid tumors, dose-limiting toxicities of muco-
sitis and neutropenia were observed at 460 mg/m2 (equivalent
in drug load to doxorubicin 340 mg/m2) [9]. The dose recom-
mended for further study was 350 mg/m2 (equivalent to doxo-
rubicin 260 mg/m2) [9]. No clinical signs of cardiotoxicity
were observed on study or during the follow-up period, even
among patients treated at the higher dose levels and/or for
extended periods [9]. The biological basis for the lack of
cardiotoxicity associated with aldoxorubicin treatment is un-
known. The amount of doxorubicinol generated after
aldoxorubicin administration has not previously been
measured.
Recently, a new formulation of aldoxorubicin was devel-
oped that eliminates or reduces the amount of inactive ingre-
dients, improves reconstitution, and allows for drug delivery
in a short time period (30 min). The phase 1 pharmacokinetic
study reported herein was conducted to fully evaluate the
pharmacokinetic profile in both serum and urine of the new
formulation of aldoxorubicin with additional assessment of
free doxorubicin and its metabolite, doxorubicinol, in patients
with advanced solid tumors.
Methods
Study design
This was a phase 1, open-label, single-center, pharmacokinet-
ic study of aldoxorubicin 230 or 350 mg/m2 (equivalent to
doxorubicin 170 or 260 mg/m2, respectively) in adult patients
with advanced solid tumors that have either relapsed or are
refractory to standard therapy (ClinicalTrials.gov registry no.
NCT01706835). The primary objective was to evaluate the
pharmacokinetic profile of aldoxorubicin in patients with
advanced solid tumors. The secondary objective was to eval-
uate treatment-related toxicities of aldoxorubicin in these
patients.
Ethics
The study protocol was approved by the study site’s institu-
tional review board and was conducted in accordance with
current US Food and Drug Administration regulations, Inter-
national Conference on Harmonisation Guideline for Good
Clinical Practice, the principles of the Declaration of Helsinki,
and other applicable regulations and guidelines. All patients
gave signed informed consent before enrollment in the study.
Patients
Eligible patients were 18 years of age or older, had a histo-
logically or cytologically confirmed malignant solid tumor
that had relapsed or was refractory to standard therapy, mea-
surable or evaluable disease, Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2, and life expectan-
cy of >12 weeks. Prior anthracycline therapy was allowed,
with no limitation on cumulative dose. Those who had re-
ceived prior radiation therapy had stable central nervous sys-
tem metastasis with no progression of brain metastasis by
computed tomography/magnetic resonance imaging scans
within 4 weeks of screening.Women of childbearing age were
not pregnant or lactating at screening, and used adequate birth
control methods during the study.
Patients were excluded if they had palliative surgery, che-
motherapy, immunotherapy, and/or radiation treatment within
4 weeks of screening; exposure to any investigational agent
within 30 days of screening; laboratory values at screening
that indicated impairment of liver function or bone marrow
function; clinically evident congestive heart failure (NewYork
Heart Association functional class II or higher); serious, clin-
ically significant cardiac arrhythmia or recent history (within
6 months of screening) or active coronary artery disease with
or without angina pectoris; serious myocardial dysfunction;
history of human immunodeficiency viral infection or active,
clinically significant serious infection requiring medical treat-
ment; or major surgery within 4 weeks of study drug
treatment.
Treatments, assessments, technical methods
Aldoxorubicin 230 or 350 mg/m2 was administered as a
30-min intravenous infusion on day 1 of each 21-day
cycle. The use of granulocyte colony stimulating factor
(GCSF) was allowed at the discretion of the investigator
and according to the American Society of Clinical Oncol-
ogy guidelines [10]. Blood samples for pharmacokinetic
analyses were taken immediately before the start of the
aldoxorubicin infusion, and then at 5, 15, 30, and 60 min,
and at 2, 4, 8, 12, 16, 24, 48, and 72 h after the start of the
infusion in cycle 1. Blood samples for limited pharmaco-
kinetic analyses were taken before aldoxorubicin admin-
istration, and then at 60 min and at 2, 4, and 8 h after the
start of the infusion in cycle 3. Serum concentrations of
albumin-bound doxorubicin, unbound (or free) doxorubi-
cin, and doxorubicinol were determined by high-
performance liquid chromatography tandem mass spec-
trometry for each sample. Urine samples were taken at
24, 48, and 72 h after the start of the infusion in cycle 1.
The amount of doxorubicin and doxorubicinol excreted in
urine and renal clearance was determined.
Adverse events were assessed at each scheduled clinic
visit, at which time the incidence, severity, duration, causality,
seriousness, and types of adverse events, as well as changes in
physical examination, vital signs, and clinical laboratory re-
sults were documented. Cardiac function was assessed by
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echocardiography or multigated acquisition scan on days 28
and 85, at study end or early termination, and every 2 months
thereafter.
Sample size
Eighteen patients were enrolled into this study at a single
center in the US.
Statistics
All patients who entered active treatment and received at least
one dose of aldoxorubicin and had complete pharmacokinetic
sampling were included in the pharmacokinetic analyses.
Descriptive statistics (mean, minimum, median, maximum,
standard deviations, and coefficient of variance) for the plas-
ma concentrations, and plasma and urine pharmacokinetic
parameters were calculated for both doses.
All patients who entered active treatment and received at
least one dose of aldoxorubicin were included in the safety
analyses. Safety data were summarized using descriptive
statistics.
Results
Between October 2012 and September 2013, 18 patients were
enrolled. All 18 patients were included in the safety analysis
and in the pharmacokinetics analyses of cycle 1: 11 patients in
the 230 mg/m2 cohort and 7 in the 350 mg/m2 cohort. Eleven
patients were included in the pharmacokinetics analyses of
cycle 3: 6 patients in the 230 mg/m2 cohort and 5 in the
350 mg/m2 cohort.
Baseline patient demographics and disease characteristics
are summarized in Table 1. Median age of the study popula-
tion was 61.7 years. Most patients (83.3 %) were Caucasian,
and most (88.9 %) had ECOG performance status of 0 or 1.
The most common primary tumor site was the lung, which
was diagnosed in 44.4 % of patients. Patients in the 230 mg/
m2 and the 350 mg/m2 cohorts had a median of 2 and 4 prior
chemotherapy regimens, respectively.
Results of the cycle 1 pharmacokinetic analyses are sum-
marized in Table 2. Mean plasma concentrations over time
after aldoxorubicin infusion for each dose group are shown in
Fig. 1. Following a single dose of aldoxorubicin on day 1 of
cycle 1, peak plasma concentrations (Cmax) of aldoxorubicin
were reached at a median of 0.75 h (230 mg/m2) and 1.00 h
(350 mg/m2) after the start of aldoxorubicin infusion (tmax).
The tmax of doxorubicin was 0.58 h (230 mg/m
2) and 0.68 h
(350 mg/m2). The tmax for doxorubicinol was much longer, a
median of 36.5 h (230 mg/m2) and 48.5 h (350 mg/m2). The
plasma concentration of aldoxorubicin was greater than that of
doxorubicin by about 40–to 300-fold, depending on the indi-
vidual. The plasma concentration of doxorubicinol, the main
metabolite of doxorubicin, was very near the limit of
detection.
Both Cmax and the area under the plasma doxorubicin
concentration-time curve from time 0 to infinity (AUC0-∞)
of aldoxorubicin and doxorubicin were higher with the
350 mg/m2 dose of aldoxorubicin than the 230 mg/m2 dose,
but systemic clearance (CL) and volume of distribution at
steady state (Vss) of aldoxorubicin, and apparent systemic
clearance (CL/F) and apparent volume of distribution (Vd/F)
of doxorubicin were similar between aldoxorubicin doses.
Importantly, both the Cmax and AUC0-∞ of free doxorubicin
represented a small fraction of the Cmax and AUC0-∞, respec-
tively, of albumin-bound doxorubicin. The Cmax of
doxorubicinol was also higher with the 350 mg/m2
aldoxorubicin dose, but overall plasma concentration of
doxorubicinol, as an absolute quantity and as a fraction of
free doxorubicin, was very low. The AUC0-∞ of doxorubicinol
could not be calculated.
The harmonic mean ± pseudo-standard deviation half-life
(t½) values for aldoxorubicin were similar for the 230 mg/m
2
and 350 mg/m2 doses (20.1±3.3 h vs 21.1±3.4 h). The t½
values for doxorubicin were higher with the 350 mg/m2 dose
of aldoxorubicin than with the 230 mg/m2 dose.
There were no apparent differences in pharmacokinetic
parameters between cycle 1 and cycle 3 (Fig. 2). There was
no evidence of accumulation of aldoxorubicin over multiple
cycles of administration.
Urine levels of doxorubicin and doxorubicinol over time
are summarized in Table 3. Overall, urine levels of
doxorubicinol were very low, relative to levels of free
doxorubicin.
Adverse events occurring on study are summarized in
Table 4. Of the 22 grade 3 or 4 adverse events reported, 11
(50.0 %) were deemed possibly or definitely related to study
drug. One aldoxorubicin-related serious adverse event, febrile
neutropenia, was reported; this patient did not receive GCSF
following the occurrence of this event. Two deaths from tumor
progression occurred. Although 10 (55.6 %) patients experi-
enced >5 % prolongation of QTc from baseline, none of these
events was considered clinically significant. Four (22.2 %)
patients, three in the 230-mg/m2 dose group and one in the
350-mg/m2 dose group, had QTc prolongation ≥470 ms, but
none of these events was considered clinically significant.
One patient who entered the study with QTc >470 ms had
fluctuations in QTc during treatment that stabilized to near
baseline value post-treatment. One patient experienced grade
3 tachycardia after 9 cycles; this was not considered a serious
adverse event and no specific action was taken. One (5.6 %)
patient, in the 230-mg/m2 dose group, had a decrease in left
ventricular ejection fraction from baseline of at least 10%, but
this was not considered clinically significant. Overall, there
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was little evidence of acute cardiotoxicity associated with
aldoxorubicin treatment.
Six patients had tumor responses or tumor shrinkage on
aldoxorubicin during the study. The four patients in the 230-
mg/m2 group with tumor response had completed a median of
9 cycles of treatment (range, 7–21), and of the two patients in
the 350-mg/m2 group with tumor response, one completed
5 cycles and the other 9 cycles of treatment. Three patients had
partial responses (PR) to treatment, including one diagnosed
with thyroid cancer with confirmed PR (230-mg/m2 group)
who remained on study for over 6 months (9 cycles complet-
ed), one diagnosed with mesothelioma with confirmed PR
(350-mg/m2 group) who was withdrawn from the study after
9 cycles because of paroxystical atrial fibrillation, and one
diagnosed with small-cell lung cancer (SCLC) with uncon-
firmed PR after 4 cycles (230-mg/m2 group) but progressive
disease (PD) after 7 cycles. Three patients had stable disease
with tumor shrinkage, including one diagnosed with SCLC
who remained on study for over 1 year (21 cycles completed;
230-mg/m2 group), one diagnosed with a small-cell
neuroendocrine tumor who remains on study at the time of
this report (1+ year; 230-mg/m2 group), and one diagnosed
with ovarian cancer with tumor shrinkage after 2 cycles (350-
mg/m2 group) but PD after 5 cycles.
Discussion
The pharmacokinetic analyses described in this report
show that aldoxorubicin has a mean circulating t½ of
20.1–21.1 h, a narrow mean volume of distribution of
3.96–4.08 L/m2, and a slow mean clearance rate of
0.136–0.152 L/h/m2. These characteristics suggest that
aldoxorubicin, either bound or unbound to serum albu-
min, is stable in circulation and does not accumulate to a
substantial degree in body compartments outside of the
bloodstream. Furthermore, plasma concentrations of free
doxorubicin and doxorubicinol were only small fractions
of the plasma concentration of albumin-bound doxorubi-
cin. Therefore, almost all doxorubicin in the circulation
Table 1 Baseline patient characteristics and disease characteristics (N=18)
Parameter Aldoxorubicin dose group
230 mg/m2 350 mg/m2 All patients
No. of patients 11 7 18
Median age (range), years 64.0 (34.0–75.9) 57.9 (37.3–69.4) 61.7 (34.0–75.9)
Male / female, n (%) 4 / 7 (36.4 / 63.6) 4 / 3 (57.1 / 42.9) 8 / 10 (44.4 / 55.6)
Race, n (%)
Caucasian 8 (72.7) 7 (100) 15 (83.3)
Black or African American 1 (9.1) – 1 (5.6)
Asian 2 (18.2) – 2 (11.1)
ECOG performance status, n (%)
0–1 9 (81.8) 7 (100) 16 (88.9)
2 2 (18.2) – 2 (11.1)
Tumor primary site
Esophagus 1 (9.1) – 1 (5.6)
Lung 5 (45.5)a 3 (42.9)b 8 (44.4)
Ovary – 1 (14.3) 1 (5.6)
Pancreas – 1 (14.3) 1 (5.6)
Soft tissue – 1 (14.3) 1 (5.6)
Testicle 1 (9.1) – 1 (5.6)
Thyroid 1 (9.1) – 1 (5.6)
Urothelium 1 (9.1) – 1 (5.6)
Unknownc 2 (18.2) 1 (14.3) 3 (16.7)
Median no. of prior chemotherapy regimens (range) 2 (0–5) 4 (2–8) 2 (0–8)
ECOG Eastern Cooperative Oncology Group
a Includes one diagnosis of metastatic small-cell lung cancer
b Includes one diagnosis of mesothelioma of the lung and one diagnosis of late-stage small-cell lung cancer
c “Unknown” includes neuroendocrine tumor of unknown or unspecified primary site
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remains bound to albumin via the acid-sensitive linker,
and little free doxorubicin is released in the bloodstream.
This is an important point that highlights one major ad-
vantage of the covalent bond formed between
Table 2 Pharmacokinetic parameters after aldoxorubicin infusion on day 1 of cycle 1 (N=18)















0.75 (0.58–1.5) 1.00 (0.583–2.5) 0.58 (0.58–1.5) 0.75 (0.58–0.75) 36.5c (12.5–72.5) 48.5 (12.5–72.5)
Cmax, ng/mL Mean (SD) 67,400 (5750) 105,000 (23,400) 1,200 (974) 2,470 (2040) 4.17 (6.20) 13.7 (10.4)
t½, h Harmonic mean
(pseudo-SD)
20.1 (3.28) 21.1 (3.36) 11.5 (2.83) 16.0 (6.67) NC NC
AUC0-t,
ng·h/mL
Mean (SD) 1,420,000 (197,000) 2,490,000 (623,000) 6,060 (3320) 12,000 (5810) 212 (310) 661 (581)
AUC0-∞,
ng·h/mL
Mean (SD) 1,550,000 (254,000) 2,760,000 (724,000) 8,570 (3880) 15,700 (7390) NC NC
CL, L/h/m2 Mean (SD) 0.152 (0.0249) 0.136 (0.0395) NA NA NA NA
Vss, L/m
2 Mean (SD) 4.08 (0.431) 3.96 (1.16) NA NA NA NA
CL/Fa, L/h/m2 Mean (SD) NA NA 23.2 (10.5) 20.5 (11.2) NA NA
Vd/F
a, L/m2 Mean (SD) NA NA 391 (156) 485 (178) NA NA
CL/Fb, L/h/m2 Mean (SD) NA NA 32.4 (14.6) 27.7 (15.1) NA NA
Vd/F
b, L/m2 Mean (SD) NA NA 545 (217) 653 (239) NA NA
AUC0-t area under the concentration-time curve from time 0 to the time of the last measurable plasma concentration, AUC 0-∞ area under the
concentration-time curve from time 0 to infinity, CL systemic clearance for aldoxorubicin, CL/F apparent clearance for doxorubicin, Cmax peak plasma
concentration of aldoxorubicin after dosing,NA not applicable,NC not calculated, SD standard deviation, t½ apparent half-life of aldoxorubicin, tmax time
to reach Cmax, Vd/F apparent volume of distribution of doxorubicin, Vss volume of distribution at steady state of aldoxorubicin
a Calculated using doxorubicin-equivalent dose; assumes all aldoxorubicin is hydrolyzed to doxorubicin
b Calculated using aldoxorubicin dose
c The tmax parameter for doxorubicinol was measured in 4 patients in the 230 mg/m
2 cohort
Fig. 1 Mean plasma
concentration-time profiles of
albumin-bound doxorubicin
(closed circles), free doxorubicin
(open circles), and doxorubicinol
(closed triangles) after
aldoxorubicin infusion on day 1
of cycle 1 (N=18)
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aldoxorubicin and serum albumin, that release of the drug
is conditional upon transport to an acidic environment
such as that found at the tumor site.
Our analyses show that very little doxorubicin is excreted
in the urine and it is mostly as unmetabolized drug, reinforcing
the conclusion that very little doxorubicin is released into the
Fig. 2 Comparison of mean plasma concentrations of (a) albumin-bound doxorubicin, (b) free doxorubicin, and (c) doxorubicinol at select time points
after infusion of aldoxorubicin on day 1 of cycle 1 (N=18; black bars) and on day 1 of cycle 3 (N=11; gray bars)
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circulation after administration of aldoxorubicin.
Doxorubicinol, which has been implicated in the pathogenesis
of cardiomyopathy associated with doxorubicin treatment [5,6],
can be detected only in trace amounts. The negligible quantities
of this molecule in the circulation may account for the lack of
cardiotoxicity observed thus far with aldoxorubicin treatment.
Our thorough pharmacokinetic study provided information
that doxorubicin covalently bound to albumin via a pH sensi-
tive linker is not released into the circulation to any meaning-
ful extent. The safety profile of aldoxorubicin at doxorubicin-
equivalent doses 2–to 4-fold higher than the standard doxoru-
bicin dose (75 mg/m2) appears favorable, with manageable
clinical and hematological toxicities and no evidence of clin-
ically significant acute or cumulative cardiac toxicity even in
patients who received over 6 months of therapy. At present,
aldoxorubicin is under investigation in a phase 3 randomized
controlled study of relapsed metastatic, locally advanced, or
unresectable soft tissue sarcoma (ClinicalTrials.gov registry
no. NCT02049905), a phase 2 clinical study of recurrent
SCLC (ClinicalTrials.gov registry no. NCT02200757), a
phase 2 pilot study of glioblastoma (ClinicalTrials.gov regis-
try no. NCT02014844), and a phase 2 pilot study of treatment
of HIV-related Kaposi’s sarcoma (ClinicalTrials.gov registry
no. NCT02029430). Together with the previous phase 1 ex-
perience, our study further supports the planned dosing and
schedule of aldoxorubicin for these studies with no limitation
for the number of cycles and/or cumulative doses of
aldoxorubicin.
Table 3 Urine levels of doxorubicin and doxorubicinol after aldoxorubicin infusion on day 1 of cycle 1 (N=18)
Aldoxorubicin 230 mg/m2 dose group (n=11)
Free doxorubicin, ng/mL Doxorubicinol, ng/mL
Time point Mean (SD) Median (range) Mean (SD) Median (range)
24 h 5090 (2903) 4220 (1250–10,600) 368 (233) 363 (57–836)
48 h 3077 (1527) 2995 (1350–5420) 375 (225) 341 (136–808)
72 h 1484 (700) 1585 (591–2360) 336 (185) 284 (97–625)
Aldoxorubicin 350 mg/m2 dose group (n=7)
Free doxorubicin, ng/mL Doxorubicinol, ng/mL
Time point Mean (SD) Median (range) Mean (SD) Median (range)
24 h 11514 (8876) 7650 (3480–27500) 741 (410) 747 (346–1300)
48 h 7854 (4358) 7470 (2170–14500) 1115 (783) 928 (325–2540)
72 h 3003 (2407) 2350 (832–8160) 632 (471) 506 (223–1660)
SD standard deviation
Table 4 Summary of adverse events, including cardiac events (N=18)
Aldoxorubicin dose group
230 mg/m2 (n=11) 350 mg/m2 (n=7) All patients (N=18)
Median cycles completed, n (range) 3 (2–21) 3 (1–9) 3 (1–21)
Patients with AEs, n (%) 11 (100) 7 (100) 18 (100)
Total AEs, n 165 105 270
Grade 3 or 4 AEsa, n (%b) 8 (4.8) 14 (13.3) 22 (8.1)
Serious AEsa, n (%b) 3 (1.8) 3 (2.9) 6 (2.2)
Deaths, n 2 (18.2) 0 (0) 2 (0.7)
Cardiac events, n (%)
Patients with >10 % decrease in LVEF 1 (9.1) 0 (0) 1 (5.6)
Patients with LVEF <45 % 0 (0) 0 (0) 0 (0)
Patients with >5 % prolongation of QTc from baseline 6 (54.5) 4 (57.1) 10 (55.6)
Patients with QTc ≥500 ms 1 (9.1) 0 (0) 1 (5.6)
AE adverse event, LVEF left ventricular ejection fraction
a Does not include deaths
b Percentage of total AEs
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